Ardelyx

Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery

AnalystLowTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystLowTarget's Fair Value

US$8.00

22.5% undervalued

24 Aug

US$6.20

-0.3%

5.8%

-0.3%

5.8%

Author's Valuation

US$8.0

22.5% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$8.0

22.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.83%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.90%

Calculation

US$56.70m

Earnings '28

43.61x

PE Ratio '28

US$2.47b

Market Cap '28

US$2.47b

Market Cap '28

253.81m

No. shares '28

US$9.74

Share Price '28

US$9.74 Share Price '28

Discounted to 2025 @ 6.90% p.a.

US$7.97

Fair Value '25